Ophthalmological composition
    1.
    发明授权
    Ophthalmological composition 有权
    眼科学成分

    公开(公告)号:US08207119B2

    公开(公告)日:2012-06-26

    申请号:US12559704

    申请日:2009-09-15

    摘要: An object is to find the minimum activity expression site of fibronectin, clarify the actions of this minimum unit in relation to opthalmological fields, and provide an opthalmological composition having this minimum unit as an effective component. This invention provides an opthalmological composition, in particular, a corneal disorder treatment agent containing the peptide, PHSRN (SEQ ID NO: 1) (Pro-His-Ser-Arg-Asn (SEQ ID NO: 1)), or Ac-Pro-His-Ser-Arg-Asn-NH2, which is a derivative thereof, or a salt thereof that is allowable as a medical drug as an effective component. The preferred dosage form is an ophthalmic formulation.

    摘要翻译: 目的是找到纤维连接蛋白的最小活性表达位点,阐明该最小单位与眼科学领域相关的作用,并提供具有该最小单位作为有效成分的眼科学成分。 本发明提供一种眼科学组合物,特别是含有肽PHSRN(SEQ ID NO:1)(Pro-His-Ser-Arg-Asn(SEQ ID NO:1))或Ac-Pro的角膜病症治疗剂 作为其衍生物的-His-Ser-Arg-Asn-NH 2或其作为医药用作有效成分的盐。 优选的剂型是眼用制剂。

    OPHTHALMOLOGICAL COMPOSITION
    2.
    发明申请
    OPHTHALMOLOGICAL COMPOSITION 有权
    眼科学组成

    公开(公告)号:US20100099629A1

    公开(公告)日:2010-04-22

    申请号:US12559704

    申请日:2009-09-15

    IPC分类号: A61K38/08 A61P27/02

    摘要: An object is to find the minimum activity expression site of fibronectin, clarify the actions of this minimum unit in relation to opthalmological fields, and provide an opthalmological composition having this minimum unit as an effective component. This invention provides an opthalmological composition, in particular, a corneal disorder treatment agent containing the peptide, PHSRN (SEQ ID NO: 1) (Pro-His-Ser-Arg-Asn (SEQ ID NO: 1)), or Ac-Pro-His-Ser-Arg-Asn-NH2, which is a derivative thereof, or a salt thereof that is allowable as a medical drug as an effective component. The preferred dosage form is an ophthalmic formulation.

    摘要翻译: 目的是找到纤维连接蛋白的最小活性表达位点,阐明该最小单位与眼科学领域相关的作用,并提供具有该最小单位作为有效成分的眼科学成分。 本发明提供一种眼科学组合物,特别是含有肽PHSRN(SEQ ID NO:1)(Pro-His-Ser-Arg-Asn(SEQ ID NO:1))或Ac-Pro的角膜病症治疗剂 作为其衍生物的-His-Ser-Arg-Asn-NH 2或其作为医药用作有效成分的盐。 优选的剂型是眼用制剂。

    Ophthalmic therapeutic composition
    5.
    发明申请
    Ophthalmic therapeutic composition 审中-公开
    眼科治疗组合物

    公开(公告)号:US20060234945A1

    公开(公告)日:2006-10-19

    申请号:US10540446

    申请日:2003-12-24

    IPC分类号: A61K38/08

    摘要: An object is to find the minimum activity expression site of fibronectin, clarify the actions of this minimum unit in relation to ophthalmological fields, and provide a ophthalmological composition having this minimum unit as an effective component. This invention provides an ophthalmological composition, in particular, a corneal disorder treatment agent containing the peptide, PHSRN (SEQ ID NO: 1)(Pro-His-Ser-Arg-Asn (SEQ ID NO: 1)), or Ac-Pro-His-Ser-Arg-Asn-NH2, which is a derivative thereof, or a salt thereof that is allowable as a medical drug as an effective component. The preferred dosage form is an ophthalmic formulation.

    摘要翻译: 目的是找到纤维连接蛋白的最小活性表达位点,阐明该最小单位与眼科领域相关的作用,并提供具有该最小单位作为有效成分的眼科学组合物。 本发明提供了一种眼科学组合物,特别是含有肽PHSRN(SEQ ID NO:1)(Pro-His-Ser-Arg-Asn(SEQ ID NO:1))或Ac-Pro的角膜病症治疗剂 作为其药物作为有效成分允许的作为其衍生物的盐酸-His-Ser-Arg-Asn-NH 2或其盐。 优选的剂型是眼用制剂。